Dermo-cosmetic spray containing Rhealba oat plantlets and Uncaria tomentosa extract in patients with mild-to-moderate cutaneous pain

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F22%3A10442550" target="_blank" >RIV/00064165:_____/22:10442550 - isvavai.cz</a>

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=MGSTjpaKgq" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=MGSTjpaKgq</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/jdv.17876" target="_blank" >10.1111/jdv.17876</a>

Result language

angličtina

Original language name

Dermo-cosmetic spray containing Rhealba oat plantlets and Uncaria tomentosa extract in patients with mild-to-moderate cutaneous pain

Original language description

Background: Chronic cutaneous pain has a substantial negative impact on quality of life (QoL). Dermo-cosmetics can support therapies for treatment of chronic skin diseases, providing symptomatic relief from chronic cutaneous pain and improved QoL. Objectives: To assess the global tolerance and efficacy of a dermo-cosmetic spray containing Rhealba® Oat Plantlet and Uncaria tomentosa extracts in reducing cutaneous pain when used as a monotherapy or in association with drug or dermo-cosmetic treatments in patients with an underlying skin pathology. Methods: Patients aged ≥1 month with a cutaneous pain level ≥3 and an underlying skin pathology were provided with the spray to use up to six times daily for 6–8 weeks. Immediate effect on cutaneous pain and patient satisfaction were assessed after the first application. Global efficacy and tolerance, reduction in symptoms, improvement in QoL, pain reduction and patient overall satisfaction were assessed after 6–8 weeks. Results: Immediately after the first application, significant reductions in cutaneous pain were observed across all age groups (P &lt; 0.0001), with 94% of patients reporting a reduction in pain. After 6–8 weeks, global tolerance was rated ‘very good’ or ‘good’ for 97% of patients, and the spray was efficacious in 95% of patients. Patient satisfaction with the efficacy of the spray was 95%. QoL scores improved in 86% and 94% of patients aged ≥12 and &lt;12 years, respectively. Findings were similar across underlying pathology and therapy types (monotherapy or in association with another therapy). Conclusions: The spray was well-tolerated and efficacious in providing symptom relief in patients with mild-to-moderate cutaneous pain, irrespective of the underlying pathology or therapy type.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30216 - Dermatology and venereal diseases

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of the European Academy of Dermatology and Venereology

ISSN

0926-9959

e-ISSN

1468-3083

Volume of the periodical

36

Issue of the periodical within the volume

S4

Country of publishing house

GB - UNITED KINGDOM

Number of pages

9

Pages from-to

3-11

UT code for WoS article

000755955800002

EID of the result in the Scopus database

2-s2.0-85124776867